Literature DB >> 2106534

Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia.

E M Kahn1, S C Schulz, J M Perel, J E Alexander.   

Abstract

Serum haloperidol levels were measured in patients who received haloperidol alone and, subsequently, haloperidol in combination with carbamazepine or lithium carbonate. Haloperidol levels and the level- dose ratios dropped about 50% in patients receiving carbamazepine. They remained the same in most patients receiving lithium carbonate. One patient receiving added carbamazepine experienced worsening of symptoms; this was associated with a drop in serum haloperidol level. Two other patients receiving added carbamazepine showed significant symptom reduction, although they also sustained drops in serum haloperidol levels. It is not clear whether these two individuals benefited from a primary antipsychotic effect of carbamazepine or from reduction of "toxic" haloperidol levels. Serum levels of antipsychotic medication should be monitored carefully when these medications are prescribed in combination with carbamazepine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106534     DOI: 10.1097/00004714-199002000-00011

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  9 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.

Authors:  J J Miceli; R J Anziano; L Robarge; R A Hansen; A Laurent
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

Review 3.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Metabolism and excretion of mood stabilizers and new anticonvulsants.

Authors:  T A Ketter; M A Frye; G Corá-Locatelli; T A Kimbrell; R M Post
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 5.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

6.  Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

Authors:  W Daniel; L Janczar; L Danek; W Legrum; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

Review 7.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

8.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

Review 9.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.